Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026232 · ClinicalTrials.gov registry record · NA
Metabolic Effects of Hydroxychloroquine
A NA study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02026232: Clinical Trial NA study, sponsored by Washington University School of Medicine.
NCT02026232 is a NA study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02026232, a NA study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The basic plan of the study is to randomize otherwise healthy subjects with type 2 diabetes to hydroxychloroquine, 200 mg twice daily or placebo.
Primary Outcome
determined by fasting blood glucose performed at baseline and follow-up
Interventions
- DRUG Hydroxychloroquine
- OTHER Hydroxychloroquine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-03 |
| Est. Completion | 2022-12-15 |
| Phase | NA |
Why NCT02026232 stopped before completion
NCT02026232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Hydroxychloroquine is the first listed.
NCT02026232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02026232 about?
NCT02026232 is a clinical study titled "Metabolic Effects of Hydroxychloroquine". The basic plan of the study is to randomize otherwise healthy subjects with type 2 diabetes to hydroxychloroquine, 200 mg twice daily or placebo.
What is the current status of trial NCT02026232?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2012-03. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT02026232?
The interventions under investigation include: Hydroxychloroquine (DRUG), Hydroxychloroquine Placebo (OTHER).
Who is sponsoring clinical trial NCT02026232?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02026232's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia